Bivalent bovine viral diarrhea virus E2 subunit vaccine, preparation method and application
By expressing the bivalent bovine viral diarrhea virus antigen protein combination in yeast, the existing vaccines have solved the problem of insufficient protection and high cost of immune system BVDV against type 2, and the simultaneous immune effect and economic value of type 1 and type 2 viruses are achieved. .
Patent Information
- Application Number
- CN202410746004.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-11
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-06-11
AI Technical Summary
The existing bovine viral diarrhea virus vaccines mainly target type 1 BVDV antigen, ignore the immune protection of type 2 BVDV, and have high cost problems in the development of veterinary vaccines.
A bivalent bovine viral diarrhea virus antigen protein combination, including 1m subtype and 2a subtype BVDV E2 protein, was recombined through the yeast expression plasmid pPIC9K to obtain a bivalent subunit vaccine, reducing production costs and improving immune effect.
The simultaneous immunization effect of BVDV-1 and BVDV-2 viruses was achieved, which reduced the complexity and cost of production processes, overcome the problem of poor prevention and control of a single E2 protein, and improved the prevention and control effect of the vaccine.
Smart Images

Figure CN118620043B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of veterinary biological products, and in particular to a bivalent bovine viral diarrhea virus E2 subunit vaccine, a preparation method and an application thereof. Background Art
[0002] Bovine viral diarrhea (BVD) is a globally distributed infectious disease caused by bovine viral diarrhea virus (BVDV), a single-stranded positive-strand RNA virus that mainly infects cattle, sheep, pigs and other ruminants. BVDV not only causes clinical symptoms such as high fever, cough, diarrhea, and abortion in female animals, but also causes persistent infection (PI) in calves, leading to immunosuppression. The disease has a wide range of infection, spreads quickly, and lacks treatment. It is one of the important animal diseases that the cattle industry must prevent and control. my country has classified BVDV as a Class II infectious disease, and the World Organisation for Animal Health (WOAH) has listed it as a legally notifiable cause of disease. BVDV causes huge economic losses to the cattle industry every year, so controlling BVDV infection is of great significance to the cattle industry.
[0003] BVDV is a single-stranded positive-strand RNA virus with a length of about 12.3 kb. The open reading frame (ORF) of the BVDV genome encodes a large polyprotein, which is translated and processed to form 12 proteins, including C, Ems, E1, E2, Npro, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B. Among them, the E2 protein is located on the outer surface of the virus and is the most important immune protective antigen of the virus, which can induce the body to produce neutralizing antibodies. BVDV is divided into three genotypes: BVDV-1, BVDV-2, and BVDV-3. At present, 22 BVDV-1 subtypes (1a-1v), 4 BVDV-2 subtypes (2a-2d), and 4 BVDV-3 subtypes (3a-3b) have been identified. Epidemiological data show that the 1m gene subtype is the most widespread gene subtype in my country. In addition, the prevalence of 2a subtype BVDV is also high in Xinjiang, Shandong, Jiangsu, Henan, Qinghai and other provinces (autonomous regions) in my country.
[0004] Vaccination is an effective method to prevent BVDV infection. In order to prevent abortion in female livestock and the production of persistently infected animals, vaccination of cows and calves is of utmost importance. This requires the use of inactivated vaccines or subunit vaccines with high safety performance. Unlike live attenuated vaccines or inactivated vaccines, "subunit" vaccines do not contain the entire pathogen, but only contain antigenic parts, such as proteins, polysaccharides or polypeptides. Since the vaccine does not contain the "live" components of the pathogen, there is no risk of introducing the disease, and it is safer and more stable than vaccines containing complete pathogens. Since BVDV has many subtypes and mutates quickly, and subunit vaccines have a short production cycle, they can quickly develop epidemic prevention products for epidemic strains, so they can be used for BVDV vaccine development. Studies have shown that BVDV antigen proteins are glycosylated proteins, and the glycosylation of E2 proteins is a key factor affecting the immune efficacy of antigens. The commercial vaccine used in my country to prevent bovine viral diarrhea is a type 1 BVD inactivated vaccine, and there is no epidemic prevention product for type 2 BVDV. Most of the products currently under development mainly use the type 1 BVDV antigen E2 or add the type 1 strain Erns antigen to enhance antigenicity, but ignore the antagonistic effect of the ribonuclease activity of the Ens protein itself on natural immunity, and also ignore the immune protection of recombinant antigens against type 2 strains. In order to solve the glycosylation of the antigen protein E2, most of them use CHO cells and insect cell expression systems, which have the defect of high cost in the development of veterinary vaccines. Summary of the invention
[0005] In view of the above-mentioned prior art, the purpose of the present invention is a bivalent bovine viral diarrhea virus E2 subunit vaccine, a preparation method and an application thereof.
[0006] To achieve the above object, the present invention adopts the following technical solution:
[0007] In a first aspect of the present invention, a bivalent bovine viral diarrhea virus antigen protein combination is provided, wherein the bivalent bovine viral diarrhea virus antigen protein combination consists of a 1m subtype BVDV E2 protein and a 2a subtype BVDV E2 protein and corresponding tags;
[0008] The amino acid sequences of the 1m subtype BVDV E2 protein and the 2a subtype BVDV E2 protein are shown in SEQ ID NO: 1 and SEQ ID NO: 2; the amino acid sequences of the 1m subtype BVDV E2 protein and the 2a subtype BVDV E2 protein and the corresponding tags are shown in SEQ ID NO: 6 and SEQ ID NO: 7.
[0009] The second aspect of the present invention provides the use of the bivalent bovine viral diarrhea virus antigen protein combination in the preparation of a subunit vaccine.
[0010] The third aspect of the present invention provides a bivalent bovine viral diarrhea virus vaccine, which is an E2 subunit vaccine, and the E2 subunit vaccine contains proteins with amino acid sequences of SEQ ID NO: 6 and SEQ ID NO: 7 as active ingredients.
[0011] Furthermore, the bovine viral diarrhea virus vaccine contains an adjuvant or a signal amplification component.
[0012] Furthermore, the bovine viral diarrhea virus vaccine is administered by injection.
[0013] The fourth aspect of the present invention provides a method for preparing a bivalent bovine viral diarrhea virus E2 subunit vaccine, which is prepared by the following steps:
[0014] The protein coding gene was processed, the linker coding sequence was added and the tag sequence was added, and then cloned into the yeast expression plasmid pPIC9K to obtain a recombinant plasmid, which was introduced into the target strain GS115 for culture and then positive clones were screened. After induction and purification, the bivalent subunits were obtained, and the E2 subunit vaccine of bovine viral diarrhea virus was obtained by emulsification with an adjuvant.
[0015] The nucleotide sequences of the protein encoding genes are SEQ ID NO: 3 and SEQ ID NO: 4;
[0016] After adding the linker coding sequence and the tag sequence, the gene sequence is SEQ ID NO:5; after the linker is cut, the amino acid sequence of the protein is SEQ ID NO:6 and SEQ ID NO:7.
[0017] The fifth aspect of the present invention provides the use of the bovine viral diarrhea virus E2 subunit vaccine in the preparation of a product for preventing bovine viral diarrhea.
[0018] Beneficial effects of the present invention:
[0019] The present invention selects E2 protein domain sequences belonging to BVDV-1 and BVDV-2, and uses them to construct recombinant plasmid pPIC9K-X. The recombinant plasmid expresses bivalent BVDV E2 antigen in Pichia pastoris, which is automatically split into bivalent subunits. The purified protein is used as the antigen of the subunit vaccine. After testing, the vaccine can be used to immunize BVDV-1 and BVDV-2 viruses at the same time, and the immune efficacy is equivalent to the effect of using BVDV-1 and BVDV-2 respectively. Unlike the bivalent inactivated vaccine that needs to cultivate two live viruses, the present invention only needs to cultivate one bacterium to produce bivalent subunit antigens, which is the same as the bivalent inactivated antigen in terms of immune effect, reduces the complexity of the production process, and saves production costs. The subunit vaccine prepared by the present invention solves the glycosylation problem of E2 protein, overcomes the shortcomings of using a single E2 protein with poor prevention and control and inability to prevent and control different types of viruses, avoids the high cost defects caused by other eukaryotic systems, and improves the prevention and control effect, which has important economic value and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is the PCR identification diagram of pPIC9K-BVDV positive clones.
[0021] Figure 2 It is the SDS-PAGE electrophoresis of TCA (trichloroacetic acid) precipitation of small-scale expression supernatant of positive clones; among them, lane 1 is the yeast cell control, lanes 1 to 9 are the positive yeast induced products with different strain numbers; lane M is the protein marker.
[0022] Figure 3 For the SDS-PAGE detection of purified recombinant protein, M is a protein marker; Lane 1 is purified protein; Lane 2 is purified concentrated protein (the red arrows point to the recombinant protein, where the 32 kDa protein is encoded by SEQ ID NO: 6 and the 10 kDa protein is encoded by SEQ ID NO: 7).
[0023] Figure 4 It is a WB detection diagram of eluted protein; wherein, lane 1, BVDV purified protein; lane M, protein Marker (the red arrow points to the recombinant protein, wherein, the 32 kDa protein is encoded by SEQ ID NO: 6, and the 10 kDa protein is encoded by SEQ ID NO: 7).
[0024] Figure 5 The figure shows the immune effect determination using the ELISA method. DETAILED DESCRIPTION
[0025] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.
[0026] In order to enable those skilled in the art to more clearly understand the technical solution of the present application, the technical solution of the present application will be described in detail below in conjunction with specific embodiments.
[0027] The experimental materials used in the examples of the present invention but not specifically described are all conventional experimental materials in the art and can be purchased through commercial channels.
[0028] In my country, the main prevalent strains are BVDV-1 and BVDV-2, and BVDV-1 includes 22 BVDV-1 subtypes (1a-1v), and BVDV-2 includes 4 BVDV-2 subtypes (2a-2d). Vaccines prepared using BVDV type 1 alone can provide good protection against BVDV-1 strains, but do not have good broad-spectrum protection against BVDV type 2. Therefore, the inventors used different types of BVDV to construct subunit vaccines in order to overcome the disadvantages of using a single E2 protein, thereby forming the present invention.
[0029] Example 1: Construction of recombinant plasmid
[0030] For BVDV-1 strains, the present invention selected the widely popular amino acid sequence (SEQ ID NO: 1) and the corresponding nucleotide sequence (SEQ ID NO: 3) of the E2 protein domain from BVDV-1m; for BVDV-2 strains, the present invention selected the widely popular amino acid (SEQ ID NO: 2) and nucleotide sequence (SEQ ID NO: 4) of the E2 protein domain from BVDV-2a, as follows:
[0031] Based on the amino acid sequence (SEQ ID NO: 1) and gene sequence (SEQ ID NO. 3) of the antigenic region of BVDV-1m E2 protein and the amino acid sequence (SEQ ID NO: 2) and gene sequence (SEQ ID NO. 4) of the antigenic region of BVDV-2a E2 protein, a cleavable linker (FGAYAASPYC) was designed between SEQ ID NO: 1 and SEQ ID NO: 3 in order to automatically cleave the protein into two subunits in yeast during expression and avoid the structural influence that may be caused by the two subunits together; tag sequences 6*His+HA and HA+6*His were designed at the 5' end of SEQ ID NO: 3 and the 3' end of SEQ ID NO: 4, respectively; and finally a composite gene sequence (SEQ ID NO: 5) for expression in yeast was obtained, which was synthesized by a biological company into the EcoRI and NotI multiple cloning sites of the pPIC9K vector and named pPIC9K-X.
[0032] The sequence of SEQ ID NO: 1 is as follows:
[0033] YPDCRPDFSYAIARNEEIGPLGAEGLTTTWHEYSDRMRLKDTMVELWCKDGQFMH
[0034] LKKCAREARYLAILHTRALPTSVTFKKLFSEQGLADTIDMDDNFEFGLCPCDARPLIRGK
[0035] FNTTLLNGPAFQMVCPIGWTGTVACTLVNEDTLSTTVIRTFKRAKPFPHRHGCITQKVV
[0036] GEDLYGCVLGGNWTCIKGEQLEYKGGPVKTCRWRGHNFHKSEGLPHYPIGKCMLVNE
[0037] TGYRSVDNTTCNRDGVAIVPKGYLKCKIGDTVVQVVAMDTKLGPMPCKPYEIIQSEGP
[0038] VEKTACTFNYT
[0039] The sequence of SEQ ID NO:2 is as follows:
[0040] IKKCKWCGYDFFNSEGLPHYPIGKCMLSNESGYRYVDDTPCDRGGVAIVPSGTVKC RIGEVKVQVIATNKDLGPMPCSPDEVVASEGPVEKTACTFNYSKT
[0041] The sequence of SEQ ID NO:3 is as follows:
[0042] TACCCAGATTGCAGGCCCGATTTTTCATACGCCATAGCTAGAAATGAGGAAATC
[0043] GGCCCGTTAGGAGCTGAAGGTCTCACAACGACCTGGCACGAATACTCAGACAGGAT
[0044] GAGGCTAAAGGACACAATGGTCGAGCTTTGGTGCAAAGATGGTCAGTTCATGCACT
[0045] TAAAGAAGTGTGCAAGAGAAGCCAGGTACCTCGCCATCTTGCACACAAGAGCTCTA
[0046] CCGACATCGGTGACATTCAAAAAACTTTTCAGTGAGCAGGGACTGGCAGACACGAT
[0047] CGACATGGATGACAACTTTGAGTTCGGACTCTGCCCATGTGATGCCAGACCTCTGAT
[0048] AAGAGGCAAATTTAACACAACTTTGCTAAATGGACCGGCCTTCCAGATGGTGTGCC
[0049] CCATTGGGTGGACAGGGACCGTGGCATGTACCTTAGTCAATGAGGACACCCTGAGT
[0050] ACAACCGTAATACGGACTTTCAAGAGGGCCAAGCCTTTTCCTCATAGGCATGGCTG
[0051] CATCACACAGAAGGTGGTTGGAGAAGATCTCTATGGCTGCGTCCTAGGAGGAAACT
[0052] GGACTTGTATTAAAGGGGAGCAGCTGGAATACAAAGGGGGTCCCGTAAAGACTTGC
[0053] AGATGGCGTGGCCACAATTTCCATAAAAGTGAAGGCCTGCCTCACTACCCTATTGG
[0054] CAAGTGCATGTTGGTGAACGAGACCGGCTACCGGTCGGTAGATAATACCACCTGCA
[0055] ATAGAGATGGTGTAGCCATAGTGCCAAAGGGATATTTAAAATGTAAGATAGGGGAC
[0056] ACAGTGGTGCAAGTGGTAGCAATGGACACTAAACTCGGGCCTATGCCTTGTAAGCC
[0057] ATATGAAATAATACAAAGTGAGGGGCCTGTGGAAAAAACAGCGTGCACTTTCAATT
[0058] ACACG
[0059] The sequence of SEQ ID NO:4 is as follows:
[0060] ATCAAGAAGTGTAAGTGGTGTGGCTACGACTTCTTCAACTCAGAGGGACTGCCG
[0061] CATTACCCAATAGGTAAGTGTATGCTCAGCAATGAGAGTGGGTATAGGTATGTAGA
[0062] TGACACCCCTTGTGATAGGGGTGGCGTAGCCATAGTTCCATCAGGCACCGTGAAGT
[0063] GTAGAATAGGTGAAGTCAAGGTGCAGGTTATCGCTACTAATAAGGACTTGGGGCCC
[0064] ATGCCTTGCAGCCCAGATGAAGTAGTAGCAAGTGAAGGACCAGTGGAAAAGACGG
[0065] CATGCACGTTCAACTATTCAAAGACA
[0066] The sequence of SEQ ID NO:5 is as follows (the capital letter part is SEQ ID NO:3 and SEQ ID NO:4):
[0067] catcatcaccatcaccattacccatacgacgtcccagactacgctTACCCAGATTGCAGGCCCGATTTTTCA
[0068] TACGCCATAGCTAGAAATGAGGAAATCGGCCCGTTAGGAGCTGAAGGTCTCACAAC
[0069] GACCTGGCACGAATACTCAGACAGGATGAGGCTAAAGGACACAATGGTCGAGCTTT
[0070] GGTGCAAAGATGGTCAGTTCATGCACTTAAAGAAGTGTGCAAGAGAAGCCAGGTAC
[0071] CTCGCCATCTTGCACACAAGAGCTCTACCGACATCGGTGACATTCAAAAAACTTTTC
[0072] AGTGAGCAGGGACTGGCAGACACGATCGACATGGATGACAACTTTGAGTTCGGACT
[0073] CTGCCCATGTGATGCCAGACCTCTGATAAGAGGCAAATTTAACACAACTTTGCTAA
[0074] ATGGACCGGCCTTCCAGATGGTGTGCCCCATTGGGTGGACAGGGACCGTGGCATGT
[0075] ACCTTAGTCAATGAGGACACCCTGAGTACAACCGTAATACGGACTTTCAAGAGGGC
[0076] CAAGCCTTTTCCTCATAGGCATGGCTGCATCACACAGAAGGTGGTTGGAGAAGATC
[0077] TCTATGGCTGCGTCCTAGGAGGAAACTGGACTTGTATTAAAGGGGAGCAGCTGGAA
[0078] TACAAAGGGGGTCCCGTAAAGACTTGCAGATGGCGTGGCCACAATTTCCATAAAAG
[0079] TGAAGGCCTGCCTCACTACCCTATTGGCAAGTGCATGTTGGTGAACGAGACCGGCT
[0080] ACCGGTCGGTAGATAATACCACCTGCAATAGAGATGGTGTAGCCATAGTGCCAAAG
[0081] GGATATTTAAAATGTAAGATAGGGGACACAGTGGTGCAAGTGGTAGCAATGGACA
[0082] CTAAACTCGGGCCTATGCCTTGTAAGCCATATGAAATAATACAAAGTGAGGGGCCT
[0083] GTGGAAAAAACAGCGTGCACTTTCAATTACACGtttggggcatatgcagcctctccctactgtATCAA
[0084] GAAGTGTAAGTGGTGTGGCTACGACTTCTTCAACTCAGAGGGACTGCCGCATTACC
[0085] CAATAGGTAAGTGTATGCTCAGCAATGAGAGTGGGTATAGGTATGTAGATGACACC
[0086] CCTTGTGATAGGGGTGGCGTAGCCATAGTTCCATCAGGCACCGTGAAGTGTAGAAT
[0087] AGGTGAAGTCAAGGTGCAGGTTATCGCTACTAATAAGGACTTGGGGCCCATGCCTT
[0088] GCAGCCCAGATGAAGTAGTAGCAAGTGAAGGACCAGTGGAAAAGACGGCATGCAC
[0089] GTTCAACTATTCAAAGACAtacccatacgacgtcccagactacgctcaccaccaccaccaccactaa
[0090] The amino acid sequences of the proteins used for immunization after final purification are SEQ ID NO:6 and SEQ ID NO:7.
[0091] SEQ ID NO: 6 is derived from the E2 protein domain of BVDV-1m (lowercase letters represent protein tags), and the sequence is as follows:
[0092] hhhhhhypydvpdyaYPDCRPDFSYAIARNEEIGPLGAEGLTTTWHEYSDRMRLKDTMV
[0093] ELWCKDGQFMHLKKCAREARYLAILHTRALPTSVTFKKLFSEQGLADTIDMDDNFEFG
[0094] LCPCDARPLIRGKFNTTLLNGPAFQMVCPIGWTGTVACTLVNEDTLSTTVIRTFKRAKPF
[0095] PHRHGCITQKVVGEDLYGCVLGGNWTCIKGEQLEYKGGPVKTCRWRGHNFHKSEGLP
[0096] HYPIGKCMLVNETGYRSVDNTTCNRDGVAIVPKGYLKCKIGDTVVQVVAMDTKLGPM
[0097] PCKPYEIIQSEGPVEKTACTFNYT fgaya
[0098] SEQ ID NO: 7 is derived from the E2 protein domain of BVDV-2a (lowercase letters represent protein tags), and the sequence is as follows:
[0099] aspycIKKCKWCGYDFFNSEGLPHYPIGKCMLSNESGYRYVDDTPCDRGGVAIVPSG
[0100] TVKCRIGEVKVQVIATNKDLGPMPCSPDEVVASEGPVEKTACTFNYSKTypydvpdyahhhh
[0101] hh
[0102] Example 2: Small-scale expression and identification of positive clones
[0103] 1. Large-scale extraction of recombinant plasmids
[0104] The constructed recombinant plasmid pPIC9K-X was transformed into the TOP10 strain, spread on an LB plate (ampicillin and kanamycin resistance), and cultured at 37°C overnight; a single colony containing the recombinant plasmid was selected and added to 3 mL LB liquid culture medium, and cultured at 37°C overnight; 700 μL of bacterial solution was taken for seed preservation, and the remaining bacterial solution was inoculated into 300 mL LB liquid culture medium (ampicillin and kanamycin resistance), and cultured at 37°C overnight; the bacterial cells were collected and a large amount of plasmid was extracted.
[0105] 2. Competent electroporation and pPIC9K-BVDV positive clone screening
[0106] Select a single colony of Pichia pastoris GS115 on the BMGY streak plate and add it to 15 mL of BMGY liquid medium, and culture it at 30°C, 200 rpm for 24 h. Take 100 μL of the bacterial solution and inoculate it into 100 mL of BMGY medium, and culture it at 30°C, 200 rpm until the OD 600 The pPIC9K-X plasmid was linearized by Sac I endonuclease and then subjected to agarose gel electrophoresis to recover the digestion product; the recovered product was electrotransformed into GS115 competent cells, and the parameters were set as voltage 1500V and time 5ms; the electrotransformed cells were coated on RDB+G418 medium plates to screen pPIC9K-BVDV positive clones.
[0107] RDB+G418 medium: Weigh 182.17 g of sorbitol, add appropriate amount of deionized water to dissolve, then add 100 mL 13.6% YNB, 100 mL 20% glucose, 10 mL 100×AA, 2 mL 500×B, make up to 1 L, add G418 to a final concentration of 1 mg / mL.
[0108] 3. PCR identification of pPIC9K-BVDV positive clones
[0109] Prepare PCR reaction system, set up blank control (no plasmid template) and positive control (add 0.5 μL plasmid) for colony PCR; detect PCR products by agarose gel electrophoresis, pPIC9K-BVDV positive clone results are shown in Figure 1 .
[0110] The primer sequences used are as follows:
[0111] Primer F:5′-GACTGGTTCCAATTGACAAGC-3′; (SEQ ID NO:8)
[0112] Primer R: 5′-GCAAATGGCATTCTGACATCC-3′. (SEQ ID NO:9)
[0113] The PCR reaction system is shown in Table 1:
[0114] Table 1 PCR reaction system
[0115]
[0116]
[0117] The PCR steps used are shown in Table 2:
[0118] Table 2 PCR steps
[0119]
[0120] 4. Small-scale expression and identification of pPIC9K-BVDV positive clones
[0121] The positive clones identified by colony PCR were selected for seed preservation; the positive strains were inoculated into 1.5 mL of BMGY liquid culture medium and cultured at 30°C and 200 rpm for 48 h; after the bacterial solution was allowed to stand for 5 to 6 h, the supernatant was removed, 1 mL of BMMY was added, and the culture was carried out at 30°C and 200 rpm for 24 h; 200 μL of YP culture medium containing 5% methanol was added for induction, and the culture was carried out at 30°C and 200 rpm for 24 h; centrifuged at 11000 rpm for 10 min, the supernatant was taken and added with 150 μL of TCA in an ice bath for 2 h; centrifuged at 11000 rpm for 10 min, the supernatant was removed, and 200 μL of acetone was added for washing; centrifuged at 11000 rpm for 10 min, the supernatant was removed, and the solution was dried at 60°C for 15 to 20 min; 20 μL of 1× loading buffer was added for resuspending and dissolving, and SDS-PAGE was performed for detection.
[0122] The positive clones verified by PCR were induced with methanol for protein expression, and the culture supernatant was collected for TCA precipitation and then detected by SDS-PAGE electrophoresis. Figure 2 The results showed that some positive clones expressed recombinant proteins.
[0123] Example 3 Protein mass expression and purification
[0124] Protein expression
[0125] Pick a single colony with a higher positive expression level identified by PCR, inoculate it into 15mL BMGY liquid culture medium, and culture it at 30℃200rpm for 24h; take 700μL of the bacterial solution for seed preservation, and inoculate the remaining bacterial solution into 1L BMGY liquid culture medium, and culture it at 30℃200rpm for 24h; centrifuge at 8000rpm for 3min, remove the culture medium, inoculate it into 1L BMMG medium, add 200μL defoaming agent, and culture it at 30℃200rpm for 24h; add 10mL methanol for induction, and culture it at 30℃200rpm for 24h; repeat the above step, centrifuge at 8000rpm for 5min, and take the supernatant; filter with a 0.22μm filter, and concentrate to 200mL by dialysis for subsequent purification.
[0126] Recombinant protein purification
[0127] The pH of the concentrated supernatant was adjusted to 8.0 with 1M Tris (pH = 9.0); a nickel column was prepared; the supernatant protein solution was loaded at a flow rate of 1 mL / min; the column was washed with NTA-0 buffer (pH = 8.0) until the effluent contained no protein (the G250 detection solution did not change color); the column was eluted with 250 mM imidazole, and the blue segment of the G250 detection was collected; the column material was washed with 3 times column volume of deionized water, and the column was sealed with 20% ethanol; the eluate was concentrated to 1-2 mL by ultrafiltration through a 10 kDa ultrafiltration tube, and the concentrate was taken for SDS-PAGE detection.
[0128] The positive clones verified by PCR were induced with methanol for protein expression, and the culture supernatant was collected, centrifuged, filtered, concentrated and purified, and then detected by SDS-PAGE and WB.
[0129] Results Figure 3 and Figure 4 The molecular weights of the proteins after cleavage are 32 kDa and 10 kDa, and the 32 kDa and 10 kDa proteins are the target proteins.
[0130] Example 4 Immune Effect Determination
[0131] The purified target protein was emulsified with an equal amount of MerckinadeSDA-201 adjuvant as a bivalent subunit antigen. Type 1 BVDV isolate NX200901 and type 2 BVDV NX3 strain were inoculated into MDBK cells, and the cell supernatant was collected after 72 hours, inactivated with formaldehyde at a final concentration of 0.1% at 37°C for 24 hours, and emulsified with an equal amount of MerckinadeSDA-201 adjuvant as inactivated virus antigen controls.
[0132] SPF female BALB / c mice (5 mice in each group) were inoculated with 100 μL of bivalent subunit antigen containing 10 μg, 100 μL of type 1 BVDV inactivated virus antigen containing 10 μg, 100 μL of type 2 BVDV inactivated virus antigen containing 10 μg, 5 μg of type 1 BVDV inactivated virus antigen and 5 μg of type 2 BVDV inactivated virus antigen (total volume 100 μL), and 100 μL PBS (negative control) to form bivalent subunit immunization group, BVDV-1 inactivated antigen immunization group, BVDV-2 inactivated antigen immunization group, bivalent inactivated antigen group, and control group. 20 days after the first immunization, the same amount of antigen as the first immunization was used for the second immunization, and 20 days after the second immunization, whole blood was collected to separate serum for ELISA to determine the antibody level. The antigen coating was 1:10 diluted type 1 BVDV inactivated antigen and 1:10 diluted type 2 BVDV inactivated antigen, respectively. The serum to be tested was diluted 1:10 in 5% de-milked powder, 100 μL was added to the detection well, incubated at 37°C for 30 min, washed with PBST three times, and then HRP-labeled goat anti-mouse IgG was added at 1:6000 dilution. It was incubated at 37°C for 30 min, washed with PBST three times, and then TMB substrate was added. It was protected from light for 10 min, 100 μL of stop solution was added to terminate the reaction, and the OD (450 nm) absorbance was read on a microplate reader.
[0133] The results are as follows Figure 5 As shown, mice in all antigen immunization groups showed high levels of antibodies after the second immunization; when the BVDV-1 antigen was used for indirect ELISA determination, the ELISA detection level of the BVDV-2 inactivated antigen immunization group was low, while the antibody level of the bivalent subunit immunization group was equivalent to that of the BVDV-1 inactivated antigen immunization group and the bivalent inactivated antigen immunization group; when the BVDV-2 antigen was used for indirect ELISA determination, the antibody level of the BVDV-1 inactivated antigen immunization group was lower than that of the BVDV-2 inactivated antigen immunization group, while the antibody level of the bivalent subunit immunization group was higher than that of the BVDV-1 inactivated antigen immunization group and was equivalent to that of the bivalent inactivated antigen group. These results show that the bivalent subunit antigen is superior to the single type 1 or type 2 BVDV inactivated antigen in terms of broad spectrum. During the preparation process, since the subunit vaccine is operated at the cellular level, the overall culture process is relatively mature, which avoids the need for additional tedious exploration due to the use of viruses for proliferation. During production, since the present invention uses a method for tandem expression of antigen epitope proteins, a bivalent subunit antigen vaccine that acts on two subtypes of BVDV can be produced by culturing one bacteria and using one production line. Compared with a bivalent inactivated vaccine that requires separate production lines for the two viruses, the complexity of the production process is reduced and production costs are saved.
[0134] The above description is only the preferred embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims
1. A bivalent bovine viral diarrhea virus antigen protein composition, characterized in that: The bivalent bovine viral diarrhea virus antigen protein composition is composed of a 1m subtype BVDV E2 protein containing a corresponding tag and a 2a subtype BVDVE2 protein containing a corresponding tag; The amino acid sequence of the 1m subtype BVDV E2 protein containing the corresponding tag is shown in SEQ ID NO:6; the amino acid sequence of the 2a subtype BVDV E2 protein containing the corresponding tag is shown in SEQ ID NO:
7.
2. Use of the bivalent bovine viral diarrhea virus antigen protein composition according to claim 1 in the preparation of subunit vaccines.
3. A bivalent bovine viral diarrhea virus vaccine, characterized in that: The bivalent bovine viral diarrhea virus vaccine is an E2 subunit vaccine, and the E2 subunit vaccine contains proteins with amino acid sequences of SEQ ID NO: 6 and SEQ ID NO: 7 as active ingredients.
4. The bivalent bovine viral diarrhea virus vaccine according to claim 3, characterized in that: The bovine viral diarrhea virus vaccine comprises an adjuvant or a signal amplification component.
5. The bivalent bovine viral diarrhea virus vaccine according to claim 3, characterized in that: The bovine viral diarrhea virus vaccine is administered by injection.
6. A method for preparing a bivalent bovine viral diarrhea virus E2 subunit vaccine, characterized in that: Prepared by the following steps: The protein coding gene was processed, the linker coding sequence was added and the tag sequence was added, and then cloned into the yeast expression plasmid pPIC9K to obtain a recombinant plasmid, which was introduced into the target strain GS115 for culture and positive clones were screened. After induction and purification, the bivalent subunits were obtained, and emulsified with adjuvants to obtain the bovine viral diarrhea virus E2 subunit vaccine; The nucleotide sequences of the protein encoding genes are SEQ ID NO: 3 and SEQ ID NO: 4; After adding the linker coding sequence and the tag sequence, the gene sequence is SEQ ID NO: 5; after the linker is cut, the amino acid sequence of the protein is SEQ ID NO: 6 and SEQ ID NO:
7.
7. Use of the bovine viral diarrhea virus E2 subunit vaccine according to claim 6 in the preparation of a product for preventing bovine viral diarrhea.
Citation Information
Cited By
Vaccine for preventing and treating bovine viral diarrhea type I and type II and application
CN121086034A
